Australia markets close in 13 minutes

Neumora Therapeutics, Inc. (NMRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.500.00 (0.00%)
At close: 04:00PM EDT
9.49 -0.01 (-0.11%)
After hours: 05:47PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.52B
Enterprise value 1.10B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.56
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-44.12%
S&P500 52-week change 324.43%
52-week high 321.00
52-week low 38.67
50-day moving average 39.77
200-day moving average 312.97

Share statistics

Avg vol (3-month) 3582.54k
Avg vol (10-day) 3683.17k
Shares outstanding 5159.52M
Implied shares outstanding 6159.52M
Float 882.8M
% held by insiders 128.14%
% held by institutions 154.13%
Shares short (15 May 2024) 46.31M
Short ratio (15 May 2024) 410.28
Short % of float (15 May 2024) 47.57%
Short % of shares outstanding (15 May 2024) 43.96%
Shares short (prior month 15 Apr 2024) 45.87M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-31.03%
Return on equity (ttm)-64.28%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -208.43M
Net income avi to common (ttm)-254.02M
Diluted EPS (ttm)-1.59
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)422.72M
Total cash per share (mrq)2.65
Total debt (mrq)4.43M
Total debt/equity (mrq)1.04%
Current ratio (mrq)17.99
Book value per share (mrq)2.66

Cash flow statement

Operating cash flow (ttm)-173.19M
Levered free cash flow (ttm)-116.02M